Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

NCT06995976 · tracked via the Priya Life Science China tracker

Sponsor

First Affiliated Hospital of Fujian Medical University

Phase

Phase EARLY_PHASE1

Started

2025-03-01

Last updated

2025-05-30

Condition(s) studied

Malignant Tumour

Investigational drug(s) / intervention(s)

68Ga-dPNE18F-FDG →

68Ga-dPNE: Intravenous injection of 68Ga-dPNE. 68Ga-dPNE PET/CT will be used to detect tumors.

18F-FDG: Intravenous injection of 18F-FDG.18F-FDG PET/CT will be used to detect tumors.

Study summary

As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.

Eligibility

Sex

ALL

Min age

18 Years

Max age

90 Years

Healthy volunteers

Accepted

Inclusion Criteria: Signed informed consent and be able to follow up. Exclusion Criteria: Pregnant or lactational women; who suffered from severe hepatic and renal insufficiency.

Primary outcome measure(s)

SUV of tumors — Through study completion, an average of 3 months
Compare the SUV of tumors between 68Ga-dPNE PET/CT and 18F-FDG PET/CT.

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital of Fujian Medical University	Fuzhou	Fujian	Recruiting

More First Affiliated Hospital of Fujian Medical University trials in China

68Ga-NI-FAPI PET/CT: First-in-human Study Recruiting

Analgesic Efficacy of Preemptive Stepwise Infiltration Anesthesia for Perioperative Analgesia After TKA Recruiting

18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study Recruiting

PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension Recruiting

Taining Golden Lake Comprehensive Chronic Disease Management Initiative Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06995976 on ClinicalTrials.gov ↗ ← All trials in China